CLP + spironolactone

This is a **combination therapy** consisting of CLP and spironolactone. Clinical trials evaluating the combination have studied it primarily in **patients with heart failure and chronic kidney disease**. **Spironolactone** is a mineralocorticoid (aldosterone) receptor antagonist primarily used as a potassium-sparing diuretic, to treat hypertension, heart failure, and fluid retention associated with liver or kidney disease. The exact identity of "CLP" in this context is not clarified in regulatory or pharmaceutical databases, and its mechanism or full chemical identity is not specified in public sources; it appears to be an investigational product under study for its effects on sodium excretion and fecal water/sodium content in heart failure patients. The combination is studied to assess potential benefits in the management of fluid and sodium balance when standard therapies are insufficient.